Oct 29, 2019 / 09:00PM GMT
Operator
Greetings. Welcome to the Navidea First Interim Analysis Conference Call. (Operator Instructions) Please note this conference is being recorded. I will now turn the conference over to your host, Jed Latkin. Jed, you may begin.
Jed A. Latkin - Navidea Biopharmaceuticals, Inc. - CEO, COO, CFO & Director
Good afternoon, and welcome, everyone. (technical difficulty) the interest of our [new product] (inaudible) Chief Executive Officer for Navidea (technical difficulty) following our prepared remarks, (technical difficulty) I'd also like to remind you that this call will be limited to (inaudible) ongoing clinical programs (technical difficulty).
But before we begin our formal remarks, I'd like remind everyone that some of our statements on this conference call may be considered forward-looking statements within the meaning of the Section 27A of Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concerns matters that involve risks and uncertainties that could cause actual results to
Navidea Biopharmaceuticals, Inc. - Special Call Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers